Eli Lilly and Company (NYSE:LLY) Given New $900.00 Price Target at Rothschild & Co Redburn

Eli Lilly and Company (NYSE:LLY) had its price objective lifted by Rothschild & Co Redburn from $880.00 to $900.00 in a report released on Thursday morning,MarketScreener reports.

LLY has been the topic of a number of other research reports. Morgan Stanley reiterated an “overweight” rating and issued a $1,344.00 target price on shares of Eli Lilly and Company in a report on Friday, May 1st. Bank of America decreased their target price on shares of Eli Lilly and Company from $1,294.00 to $1,133.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Daiwa Securities Group upped their price target on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Guggenheim reissued a “buy” rating and set a $1,183.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday. Finally, Freedom Capital upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $1,218.33.

Eli Lilly and Company Price Performance

NYSE LLY traded down $21.04 on Thursday, reaching $953.92. 802,780 shares of the stock traded hands, compared to its average volume of 3,181,586. The firm’s fifty day simple moving average is $943.90 and its 200 day simple moving average is $990.90. The company has a market cap of $898.34 billion, a price-to-earnings ratio of 33.91, a P/E/G ratio of 1.08 and a beta of 0.48. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. During the same quarter in the prior year, the company earned $3.34 earnings per share. The firm’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, research analysts predict that Eli Lilly and Company will post 35.68 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.

Institutional Investors Weigh In On Eli Lilly and Company

A number of large investors have recently bought and sold shares of LLY. Vanguard Group Inc. lifted its holdings in Eli Lilly and Company by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after purchasing an additional 1,006,885 shares during the last quarter. State Street Corp grew its holdings in Eli Lilly and Company by 1.8% during the fourth quarter. State Street Corp now owns 35,361,916 shares of the company’s stock valued at $38,002,744,000 after purchasing an additional 635,358 shares during the last quarter. Capital Research Global Investors grew its holdings in Eli Lilly and Company by 20.9% during the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after purchasing an additional 4,332,008 shares during the last quarter. Morgan Stanley raised its position in shares of Eli Lilly and Company by 2.7% in the fourth quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock valued at $16,757,510,000 after purchasing an additional 407,166 shares during the period. Finally, Capital World Investors raised its position in shares of Eli Lilly and Company by 0.4% in the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock valued at $16,154,619,000 after purchasing an additional 61,851 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong Q1 beat-and-raise underpins bullish thesis: Lilly beat revenue and EPS expectations and raised guidance, driven by Mounjaro, Zepbound and other GLP‑1 demand — a catalyst for recent gains. LLY Stock Pops 16% After Beat-and-Raise Q1
• Positive Sentiment: Q1 revenue surge (56%) and continued volume growth from new drugs reinforce earnings power and long-term runway. LLY Reports Q1 2026 Revenue Surge
• Positive Sentiment: Analyst support: Cantor Fitzgerald recently lifted its price target after the earnings call, signaling continued Wall Street backing. Cantor Fitzgerald Lifts PT on Eli Lilly
• Positive Sentiment: Pipeline and non‑GLP-1 data helping sentiment — new ulcerative colitis (Omvoh/mirikizumab) data show durable disease clearance, supporting long-term growth beyond obesity/diabetes. Eli Lilly Advances As Inflammatory Bowel Disease Drug Reinforces Confidence
• Positive Sentiment: Capacity expansion: Lilly pledged an additional $4.5B for Indiana manufacturing (new LEAP facility and genetic medicines capacity), signaling commitment to supply for GLP‑1 and biologics. Lilly To Invest $4.5B More In Indiana Manufacturing
• Neutral Sentiment: Shareholder vote: Investors backed the board and kept the governance structure at the annual meeting — removes a governance overhang short‑term. Shareholders Back Board
• Neutral Sentiment: Strategic M&A: Coverage on the CrossBridge Bio Houston buy (≈$300M) highlights targeted deals to bolster pipeline — incremental but capital‑intensive. Meet the minds behind CrossBridge Bio
• Neutral Sentiment: Related IPO/partner news: Coverage of Omada Health’s IPO performance (a Lilly‑tied digital health deal) is informative for ecosystem exposure but has limited direct impact on LLY equity. How This Eli Lilly-Tied IPO Stock Fared
• Negative Sentiment: Valuation and competition chatter: Some pieces argue Lilly’s valuation is lofty and highlight Novo Nordisk’s strong pill launch — raising questions about upside after the big rally. Forget Eli Lilly: These 2 Stocks Have More Upside
• Negative Sentiment: Capital markets noise: Reports that Lilly may sell bonds (~$8B reported) to fund acquisitions can weigh on sentiment because of leverage/cost concerns (company statements are evolving). Market Chatter: Lilly Plans to Sell About $8B of Bonds
• Negative Sentiment: Safety/quality headlines can create short-term volatility: analysts say the market reaction to an FDA adverse event report looked overdone, but such headlines still spur trading swings. Wolfe: Market Reaction Overdone

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.